. 2014 Dec 29;6(2):123–127. doi: 10.1021/ml500340z

Table 1. Summary of the Tetrapeptide Agonist (EC₅₀) Receptor Pharmacologically at the mMC1R and mMC5R (Mean ± SEM)^a.

analogue	mMC1R agonist EC₅₀ (nM)	mMC5R agonist EC₅₀ (nM)
MTII	0.22 ± 0.14	0.57 ± 0.07
SHU9119	0.67 ± 0.11	2.4 ± 0.4
NDP-MSH (6–9)	71 ± 20	4.6 ± 1.2
1	2000 ± 600	2800 ± 1100
2	20700 ± 7400	7800 ± 2600
3	8300 ± 1900	23700 ± 4300
4	2700 ± 600	5300 ± 1500
5	6500 ± 1200	1800 ± 600
6	5500 ± 300	20300 ± 3200
7	5800 ± 1700	19700 ± 4400

The reported errors are the standard error of the mean of at least three independent experiments. MTII, SHU9119, and NDP-MSH (6–9) are included as control compounds.

Table 1. Summary of the Tetrapeptide Agonist (EC50) Receptor Pharmacologically at the mMC1R and mMC5R (Mean ± SEM)a.

Table 1. Summary of the Tetrapeptide Agonist (EC₅₀) Receptor Pharmacologically at the mMC1R and mMC5R (Mean ± SEM)^a.